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Abstract
Background: Clostridium difficile infection (CDI) is increasingly recognized as an important community acquired
pathogen causing disease (CA-CDI). Vitamin D [25(OH)D] has immune modulatory effects and plays an important
role in intestinal immunity. The role of vitamin D in CA-CDI has not been examined previously.
Methods: This was a single referral center case–control study. Cases comprised of all patients with CA-CDI who had
a serum 25(OH)D measured within 12 months prior to infection. Controls were drawn from patients who had
25(OH)D checked and matched based on age, gender, race and health status. Serum 25(OH)D was stratified
as < 15 ng/mL, 15-30 ng/mL or > 30 ng/mL. Regression models adjusting for potential confounders were used to
define independent association between vitamin D and CA-CDI.
Results: We identified 58 matched case–control pairs (66% women; 85% Caucasian). The mean age was 62 years.
The mean serum 25(OH)D level was significantly lower in CA-CDI cases compared to controls (28.5 ng/mL vs.
33.8 ng/mL, p = 0.046). Cases had higher rate of antibiotic exposure and more comorbidity. Serum 25(OH)D < 15 ng/mL
was associated with an increased risk of CA-CDI on univariate (Odds ratio (OR) 5.10, 95% confidence interval (CI)
1.51 – 17.24) and multivariate analysis (OR 3.84, 95% CI 1.10 – 13.42). Vitamin D levels between 15-30 ng/mL did not
modify disease risk.
Conclusions: Low serum 25(OH)D < 15 ng/mL was associated with increased risk of CA-CDI. This suggests vitamin D
may have a role in determining susceptibility to CA-CDI.
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Background
Clostridium difficile (C. difficile) is a gram-positive, an-
aerobic, spore-forming bacillus that has emerged as a
serious and common healthcare-associated infection
with significant morbidity [1-7]. The spectrum of illness
caused by C. difficile ranges in severity from asymptom-
atic or self-limited mild diarrhea, to fulminant colitis
and death. C. difficile infections (CDI) are costly; a retro-
spective analysis of Massachusetts hospital discharge
data demonstrated a total cost of 55,380 inpatient-days
and $51.2 million over 2 years [8]. Based on national
estimates of the numbers of patients affected by CDI,
the annual cost is roughly $3.2 billion dollars [9]. In
addition to the present disease burden, an analysis per-
formed by the Centers for Disease Control and Preven-
tion projects that, in the United States, the number of
cases of CDI continues to rise [9].
One key mechanism underlying pathogenesis of CDI is
disruption of the host microbial flora, commonly through
broad-spectrum antibiotic use [1-7]. In observational stud-
ies, between 50-95% of patients with CDI had recent ex-
posure to antibiotics or other healthcare environments
facilitating transmission of C difficile [1]. Other risk factors
remain less well established including use of acid suppres-
sive medications [10,11], underlying inflammatory bowel
disease [12,13], pregnancy or post-partum state [14-17],
and liver disease [18-20]. Yet much regarding the host risk
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factors for CDI remains inadequately defined. Host im-
mune response to C difficile in the form of antibody pro-
duction is associated with reduced rates of carriage [21].
Host genetic factors governing immune response, particu-
larly innate immunity, may also play a role in determining
susceptibility to CDI [22]. Consequently, factors that influ-
ence such host immune responses may additionally con-
tribute towards the pathogenesis of CDI.
A recent factor associated with CDI in the hospitalized
population and in those with inflammatory bowel dis-
ease (IBD) is deficient plasma vitamin D [23-25]. There
is increasing interest in the immunological role of
vitamin D particularly on the innate immune response
[26-28]. Cathelicidins are antimicrobial peptides whose
production is stimulated by vitamin D [29-31]. In labora-
tory studies, administration of exogenous cathelicidin re-
duced severity of C difficile infection [30]. Limited data
supports such an association in humans. One study
demonstrated an association between low plasma vita-
min D and CDI associated health-care costs [32], while
more recently Quraishi et al. reported an association be-
tween reduced pre-hospital plasma 25-hydroxy vitamin
D and increased risk for hospital acquired CDI (HA-CDI)
[23]. There is increasing recognition that a substantial por-
tion of CDI may occur in the community (CA-CDI) in in-
dividuals without the well-recognized risk factors for CDI
[33,34]. The role of vitamin D deficiency in predisposing
to disease risk in this population has not been examined
previously but yet is an important question to examine as
risk factors in the hospitalized patients who tend to be
older and have greater co-morbid burden may not be ap-
plicable to individuals in the community. In this retro-
spective case–control study, we examined the association
between reduced plasma 25-hydroxy vitamin D and risk of
CA-CDI.
Methods
Data source and patient population
The primary source of data for this study was electronic
medical record (EMR) data generated during patient
care episodes at Massachusetts General Hospital, a ter-
tiary referral center in the greater Boston metropolitan
area. The cases were identified by querying an internally-
maintained database of EMR data (Research Patient Data
Repository, RPDR) for patients seeking care between Jan
1, 2010 and June 30, 2013 who had a positive laboratory
assay for C. difficile toxin antigen in the stool. A diagnosis
of CDI was established by symptoms in combination with
detection of C. difficile toxin in the stool using enzyme
linked immunosorbent assay (ELISA) except during the
last year of the study when the testing algorithm switched
to a two-stage strategy with initial screen using the ELISA
for glutamate dehydrogenase (GDH) followed by the toxin
assay with the use of polymerase chain reaction (PCR) for
final determination in the setting of indeterminate toxin
assay. The RPDR is an electronic database that is automat-
ically and continuously populated with every patient en-
counter, laboratory test, radiologic or operative procedure
at a Partners Healthcare affiliated facility, and incorporates
data from billing codes, clinical laboratory, inpatient, and
outpatient stays [35]. For the purpose of this study, a case
of CA-CDI was defined as an outpatient with a positive
assay or inpatients who had a positive test within the first
48 hours of hospital admission, consistent with the defin-
ition of CA-CDI [36]. Patients with prior hospitalization
or stay at a healthcare-associated facility within the past
90 days were excluded [36]. Cases were included if they
had 25-hydroxy vitamin D [25(OH)D] measured within
1 year before or within 2 weeks after toxin positivity. We
allowed for a 2 week window for assessment of vitamin D
status after diagnosis as levels of 25(OH)D are unlikely to
change immediately after an acute infection, and levels
measured within this window are likely reflective of pre-
diagnosis vitamin D [37,38]. Controls were matched to
cases in a 1:1 ratio by age, sex, race, and health status (de-
fined via the number of health care visits in a given period
of time). None of the included patients had a prior history
of CDI.
Variables
The exposure of interest was vitamin D status assessed
as the 25(OH)D level closest in proximity to the date of
toxin positivity. As noted above, levels from one year
prior to admission to two weeks after toxin positivity
were allowed. In order to define cutoffs, we noted that
in the previous study performed by Quraishi et al., there
was an increased risk of HA-CDI only with 25(OH)D
levels <10 ng/mL, however there were very few cases
that had 25-OH-Vitamin D levels in this range [23]. As a
result, we decided to combine the bottom two groups
and use the midpoint to arrive at a cutoff of 15 ng/mL
with values below this level representing vitamin D defi-
ciency. Additionally, we used 30 ng/mL and above as
normal per Institute of Medicine guidelines. Individuals
with 25(OH)D levels between 15-30 ng/mL represent
vitamin D insufficiency. Plasma 25(OH)D was measured
using high-performance liquid chromatography with
mass spectrometry. This has previously demonstrated a
low co-efficient of variance and has been used in prior
studies from our institution [39].
Information was collected including age, gender, race
and comorbidity. Comorbidity was assessed using the
widely-used and validated Charlson Comorbidity Index
(CCI), which was computed using the recorded billing
codes for the patient prior to their CA-CDI encounter
[40]. Medication use was assessed using the electronic
prescription function of the EMR. Specifically prescriptions
for antibiotics, proton-pump inhibitors (PPI), vitamin D
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supplements, multivitamins, and statins within the 90 days
prior to admission were noted. These variables were se-
lected because multivitamin represent a source of vitamin
D supplementation and could be a confounder for ‘healthy
behaviors’ while statins have been previously shown to be
inversely associated with risk of CDI [41]. Other labora-
tory values collected included the white blood cell (WBC)
count on admission, peak WBC count, baseline serum
creatinine level or need for dialysis, peak serum creatinine
level, and serum albumin.
Statistical analysis
Statistical analyses were performed using the JMP Plat-
form (JMP 11 Professional, SAS Institute, Cary, NC) and
Stata SE 12.1 (StataCorp, College Station, TX). Continuous
variables were summarized using means and standard de-
viations, and compared using paired t-tests. Categorical
variables were expressed as proportions and compared
using Fisher’s exact tests. Plasma 25(OH)D levels were
modeled as a categorical variable with three levels (as
described above, normal, insufficiency, and deficiency).
Multivariate logistic regression was performed to adjust
for potential confounders, the final model included vari-
ables significant at p < 0.10 on univariate analysis. Logistic
regression models were created with and without adjust-
ment for antibiotic use as vitamin D deficiency has been
associated with increased risk of infections and conse-
quently antibiotic use could represent an intermediate step
in the pathway of development of CDI rather than a true
confounder [23,26]. Ethical approval was obtained from
the Institutional Review Board of Partners Healthcare.
Results
Fifty-eight cases of CA-CDI were successfully matched
with control patients. The demographic and clinical
characteristics of these groups are presented in Table 1.
Two-thirds were women (66%), and a majority was
Caucasian (85%), with a mean age of 62 years (standard
deviation (SD) 19 years). The mean 25(OH)D levels were
28.5 ng/mL (SD 15.4) in the cases, compared to 33.8 ng/mL
(SD 12.8) in the controls (p = 0.046). The cases demon-
strated higher rates of prior exposure to antibiotics, sta-
tins, and proton pump inhibitors (PPI), and greater
comorbidity.
Univariate analysis of the variable of interest and the
primary potential confounders is presented in Table 2.
Vitamin D deficiency was strongly associated with CA-CDI,
with an OR of 5.1(95% CI 1.51 – 17.24) for those with
levels below 15 ng/ml when compared to those with
levels > 30 ng/mL. Vitamin D insufficiency, i.e. levels be-
tween 15-30 ng/mL was not associated with CA-CDI,
with OR of 1.22 (95% CI 0.54 – 2.78, p = 1.0). Other vari-
ables associated with CA-CDI were use of antibiotics
(OR 10.88, 95% CI 4.60 – 25.75), statins (OR 3.28, 95%
CI 1.25 – 8.62), and PPI (OR 11.44, 95% CI 4.24 – 30.85).
The final logistic regression model adjusting for poten-
tial confounders is presented in Table 3. After adjust-
ment for season of measurement and comorbidity (with
matching on age and gender), vitamin D deficiency con-
tinued to be independently associated with CA-CDI (OR
3.84, 95% CI 1.10 – 13.43, p = 0.035). The addition of anti-
biotic exposure within the previous 90 days only weakly
attenuated the association between CA-CDI and vitamin
D deficiency (OR 3.77, 95% CI 0.92 – 15.47, p = 0.066).
Vitamin D insufficiency was not associated with CA-CDI
in either model.
Discussion
Recent studies have highlighted the immunological role
of vitamin D, its role in intestinal inflammation includ-
ing Crohn’s disease, and in determining susceptibility to
infections [26,28]. Furthermore, intriguing emerging data
Table 1 Characteristics of patients with community acquired Clostridium difficile infection (CA-CDI) and matched controls
Cases (n = 58) Controls (n = 58) p-value
Age (in years) Mean (SD) 62.1 (19.2) 62.2 (19.7) 0.99
Female n (%) 38 (65.5) 38 (65.5) 1.00
Caucasian Race n (%) 49 (84.5) 49 (84.5) 1.00
Charlson Index Mean (SD) 6.19 (4.16) 1.33 (1.63) < 0.01
Antibiotic Use n (%) 45 (77.6) 14 (24.1) < 0.01
Statin Use n (%) 18 (31.0) 7 (12.1) 0.013
PPI Use n (%) 33 (56.9) 6 (10.3) < 0.01
Supplement vitamin D use n (%) 22 (37.9) 10 (17.2) 0.013
Multivitamin Use n (%) 17 (29.3) 3 (5.2) 0.001
Baseline Albumin (g/dL) Mean (SD) 3.21 (0.77) 4.30 (0.57) < 0.01
Baseline Creatinine (mg/dL) Mean (SD) 2.37 (6.74) 0.95 (0.37) 0.12
Plasma 25(OH) D (ng/mL) Mean (SD) 28.5 (15.4) 33.8 (12.8) 0.04
SD – standard deviation; PPI – proton pump inhibitor.
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has supporting a potential role for vitamin D deficiency
in influencing susceptibility to CDI [23,25] and amelior-
ation of severity of CDI by administration of exogenous
cathelicidin, an antimicrobial peptide induced by vitamin
D [30]. In our study, we demonstrate that 25(OH) D
levels of <15 ng/mL are associated with an increased risk
for CA-CDI. This effect persists even after adjusting for
several potential confounders, supporting our hypoth-
eses that vitamin D may play a role in gut immunity,
and that vitamin D deficiency may predispose patients
to CA-CDI.
Only few studies have examined an association be-
tween vitamin D levels and susceptibility to CDI; they
have focused on the role of vitamin D deficiency in me-
diating susceptibility to CDI in hospitalized patients
[23], and in those with IBD [25]. However these findings
cannot be generalized to our cohort for several reasons.
Compared to those who acquire CDI in the hospital,
those with CA-CDI have less comorbidity and fewer risk
factors such as antibiotic exposure predisposing to dis-
ruption of the enteric microbiome. Similarly, the patient
population with IBD-CDI arguably has altered gut immune
responses and microbiome when compared to those in
the community who develop CDI. Two studies have
examined the effect of vitamin D deficiency on CDI out-
comes. From a hospitalized cohort with C difficile infec-
tion, van der Wilden et al. noted a higher frequency of
vitamin D deficiency in those with severe disease defined
as abdominal computed tomography scan findings of col-
itis [24]. A prior study examining healthcare costs sug-
gested that vitamin D-deficient patients with CDI incurred
costs more than five times higher than the non-deficient
patients, had longer hospital stay and greater number of
hospitalizations [32]. In our study, we did not identify any
association between vitamin D deficiency and severity of
CA-CDI, but larger cohorts are likely required to more ac-
curately define this association.
Considerable evidence supports this hypothesis at the
molecular level. Most cells involved in immune re-
sponses including B-lymphocytes, T-lymphocytes, den-
dritic cells, and monocytes carry vitamin D receptors
(VDR) [26,28]. Furthermore, vitamin D stimulates the
expression of potent antimicrobial peptides, cathelici-
dins. Cathelicidins are a family of peptides thought to be
part of an innate defensive barrier against potential mi-
crobial pathogens (bacteria, viruses, fungi alike) and are
present at skin and mucosa of the gastrointestinal and
respiratory tracts [30,31,42,43].
In a recent study, Hing et al. demonstrated reductions
in c difficile related colonic damage at the histologic
level, cell apoptosis, tissue myeloperoxidase levels and
tumor necrosis factor α levels with cathelicidin adminis-
tration in wild-type mice [30]. Also using mouse models,
Ooi et al. showed that vitamin D availability combined
with normally functioning vitamin D receptors is re-
quired for the development of regulatory T-lymphocytes
[44]. With vitamin D- or vitamin D-receptor deficiency,
these immune responses are impaired and affected mice
are susceptible to immune-mediated diseases of the in-
testinal tract [44]. Additionally, vitamin D protects mac-
rophages against death from C difficile toxin- induced
intestinal injury [45]. All of these mechanisms in addition
to others yet undiscovered may help explain the associ-
ation between vitamin D deficiency and CDI.
Further implications of our findings include the poten-
tial impact preventive medicine can play curtailing the
rates of CDI. Taken together, both HA-CDI and CA-CDI
appear to be associated with vitamin D deficient status. If
additionally confirmed in other cohorts, routine screening
for vitamin D deficiency in primary care offices (already
under way in many practices in the United States) can lead
to vitamin D supplementation where indicated and
achieve a vitamin D replete state. In light of the substantial
costs associated with CDI, this outpatient intervention
could potentially have significant financial implications,
Table 2 Univariate logistic regression of predictors of







> 30 ng/mL 1.0
15-30 ng/mL 1.22 0.54 – 2.78 0.63
<15 ng/mL 5.10 1.51 – 17.23 0.009
Charlson Index ≥1 4.92 1.81 – 13.38 0.002
Antibiotic Use 10.88 4.60 – 25.75 < 0.001
Statin Use 3.28 1.25 – 8.62 0.016
Proton pump inhibitor use 11.44 4.24 – 30.85 < 0.001
Baseline Albumin
(for each 1 g/dL increase)
0.11 0.04 – 0.24 < 0.001
Baseline Creatinine
(for each 1 mg/dL increase)
1.85 1.07 – 3.16 0.027
Table 3 Multivariate logistic regression of predictors of







> 30 ng/mL 1.0
15-30 ng/mL 1.09 0.45 – 2.62 0.845
<15 ng/mL 3.84 1.10 – 13.42 0.035
Charlson Index ≥1 4.13 1.47 – 11.61 0.007
Winter 1.00 0.44 – 2.28 0.995
+Model adjusting for co-morbidity, season of vitamin D measurement. Patients
were additionally matched on age, gender, and health status.
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particularly in groups at high risk for CDI. Thus, whether
there is a role for routine supplementation of vitamin D,
either in primary prevention, or in improvement of out-
comes in those with established disease merit further
study. As well, mechanistic studies examining the down-
stream effects of vitamin D, either through the vitamin D
receptor or through stimulation of production of cathelici-
dins, may help shed further light on host immune factors
that influence susceptibility to C difficile infections.
The most significant limitation of this study is the
small sample size. Although this did not impact the ob-
served effect size, it did limit the ability to adjust for
multiple confounders. Additional limitations include the
retrospective nature of the analysis, which introduces
some degree of bias due to completeness of documenta-
tion at the time of the original clinical encounter. Also,
measurement of vitamin D levels was as part of routine
clinical care. Thus, the population having a measured
level may differ from the general population in commu-
nity. However, we would expect this to likely be similar
across both the case and control population and not re-
sult in a biased association. As in any observational
study, there is the possibility for unmeasured con-
founders. We were able to adjust for most of the rele-
vant variables including age, co-morbidity, antibiotic use
and recent healthcare exposure. Additionally, this is a
cross-sectional study, which does not allow for estima-
tion of absolute risks or inference of causality. Finally, it
is possible that patients who initially had deficient
vitamin D levels were recommended supplementation
which may have increased their levels by the time of de-
velopment of CA-CDI. However, we believe this is un-
likely to influence our findings for two reasons. Our
results were robust on adjustment for supplemental vita-
min D or multivitamin use, two commonly recom-
mended methods for supplementing vitamin D levels.
Second, such misclassification would actually bias our
results towards the null making our effect sizes a more
conservative estimate.
Conclusions
In summary, patients with CA-CDI were more likely to
have vitamin D deficiency (<15 ng/mL), and this associ-
ation persisted as an independent risk factor in logistic
regression models even after adjusting for potential con-
founders. Further prospective studies are needed to con-
firm our findings. As well, additional studies are also
needed to establish mechanisms through which vitamin
D mediates gut immunity and susceptibility to enteric
infections and intestinal inflammation. Human studies
of the role of vitamin D assessment in supplementation,
particularly in those at high risk of C difficile infection,
may be warranted supported by the emerging literature
in this field.
Clinical relevancy statement
Clostridium difficile infection (CDI) is an important
cause of morbidity and mortality. While commonly rec-
ognized as a hospital acquired infection, up to 40% of
CDI could be acquired in the community by individuals
with no extrinsic risk factors. Thus, identification of po-
tential host factors that predispose to CDI is an import-
ant goal. In this study, we demonstrate low vitamin D to
be associated with increased risk of CDI. Once con-
firmed in additional independent cohorts, this may form
a basis for future clinical trials of vitamin D in the pre-
vention and treatment of CDI. It may also help labora-
tory studies aiming to understand the host response to
C difficile. This finding is clinical relevant to guide clini-
cians to routinely monitor vitamin D status in those at
risk for C difficile.
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